期刊文献+

对甲苯磺酸索拉非尼的合成 被引量:11

Synthesis of Sorafenib Tosylate
原文传递
导出
摘要 4-氯-3-三氟甲基苯胺(5)和氯甲酸苯酯反应得到[4-氯-3-(三氟甲基)苯基]氨基甲酸苯酯(6),再和对氨基苯酚缩合得到N-[4-氯-3-(三氟甲基)苯基]-N-(4-羟基苯基)脲(7)。另用2-吡啶甲酸(2)经氯化、酰胺化得中间体N-甲基-(4-氯-2-吡啶基)甲酰胺(4)。4和7经亲核取代及成盐反应制得对甲苯磺酸索拉非尼,总收率约62%(以5计)。 N- [4-Chloro-3- (trifluoromethyl) pheny1] -N'- (4-hydroxyphenyl) urea (7) was prepared from 4-chloro- 3-(trifluoromethyl) aniline by reaction with phenyl chloroformate and condensation with 4-aminophenol. Meanwhile, N-methyl- (4-chloropyridin-2-yl) carboxamide (4) was prepared from 2-picolinic acid (2) by chlorination and amidation. Sorafenib tosylate was synthesized from 4 and 7 by condensation and salt formation with an overall yield of about 62 % [based on 4-chloro-3- (trifluoromethyl) aniline].
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2012年第7期521-524,共4页 Chinese Journal of Pharmaceuticals
基金 国家"重大新药创制"科研重大专项(2009ZX09301-007)
关键词 索拉非尼 抗肿瘤药 合成 sorafenib antitumor agent synthesis
  • 相关文献

参考文献10

  • 1王芳,符立梧.多靶点抗肿瘤新药索拉非尼的研究进展[J].中国药理学通报,2008,24(8):1117-1120. 被引量:24
  • 2Riedl B, Dumas J, Khire U, et al. Omega-carboxyaryl substi- tuted diphenyl ureas as Rafinhibitors: US, 20010016659 EP]. 2001-08-23.
  • 3Monahan MK, Sibley R, Natero R, et al. A scalable synthesis of bay 43-9006: a potent rafkinase inhibitor for the treatment of cancer [J]. Org Process Res Dev, 2002, 6 (6) : 777-781.
  • 4Wilhelm S, Dumas J, Ladouceur G, et al. Diaryl ureas with kinase inhibiting activity: WO, 2004113274 [Pl. 2004-12-29.
  • 5Dumas J, Scott W J, Elting J, et al. Aryl ureas with angio- genesis inhibiting activity: WO, 2003068228 [P]. 2003-08-21.
  • 6Logers M, Gehring R, Kuhn O, et al. Process for the prepa- ration of a Raf kinase inhibitor and intermediates for use in the process: WO, 2006034796 [P]. 2006-04-06.
  • 7赵乘有,陈林捷,许煦,罗晓燕,冀亚飞.对甲苯磺酸索拉非尼的合成[J].中国医药工业杂志,2007,38(9):614-616. 被引量:15
  • 8Rao DR, Kankan RN, Ghagare S, et al. Process the preparation of a Raf kinase inhibitor and intermediates for use in the process: WO, 2009034308 [P]. 2009-03-19.
  • 9Muddasani PR, Nannapanenl VC. Novel process for the preparation of sorafenib: WO, 2009054004 [P]. 2009-04-30.
  • 10王博,罗宇.索拉非尼的合成方法:中国,101671299[P].2010.03-17.

二级参考文献35

  • 1王绪根,谭心舜.异氰酸酯的反应动力学研究[J].青岛科技大学学报(自然科学版),2005,26(5):382-385. 被引量:6
  • 2钟敏.未来的重磅炸弹级药物[J].上海医药,2006,27(2):80-83. 被引量:3
  • 3吕允凤,封宇飞,胡欣,毕开顺.索拉非尼的药理及临床研究[J].中国新药杂志,2007,16(1):88-91. 被引量:16
  • 4Bankston D,Dumas J,Natero R,et al.A scaleable synthesis of Bay 43-9006:a potent raf kinase inhibitor for the treatment of cancer[J].Org Process Res Dev,2002,6(6):777-781.
  • 5Riedl B,Dumas J,Khire U,et al.Omega-carboxyaryl substituted diphenyl ureas as raf inhibitors:US,2003207872[P].2003-11-06.(CA 2003,139:364958)
  • 6Wilhelm S,Dumas J,Ladouceur G,et al.Diaryl ureas with kinase inhibiting activity; WO,2004113274[P].2004-12-29.(CA 2005,142:93545)
  • 7Loegers M,Gehring R,Kuhn O,et al.Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl] amino } carbonyl) amino] phenoxy }-N-methylpyr-idine-2-carboxamide:WO,2006034796[P].2006-04-06.(CA 2006,144:369917)
  • 8Werntz JH.Fluoroaromatic isoyanates:US,2625561[P].1953-01-13.(CA 1953,47:11243c)
  • 9Wilhelm S M,Carter C,Tang L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[ J]. Cancer Res,2004,64(19) :7099 - 109.
  • 10Strumberg D, Clark J W, Schwartz B, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib : a review of four phase I trial in patients with advanced refractory solid tumors[J]. Oncologist,2007,12 (4) :426 - 37.

共引文献38

同被引文献67

引证文献11

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部